Work

Nivolumab (nivo) + nab-paclitaxel (nab-P) + carboplatin (C) in patients (pts) with non-small cell lung cancer (NSCLC): Interim results from a multicenter phase I study.

Year: 2017

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2017.35.15_suppl.9095

Authors: David Michael Waterhouse, Jonathan Wade Goldman, Ben George, Peter J. O'Dwyer, Moncy Ye, Tianlei Chen, Nataliya Trunova, Karen Kelly

Institutions: Oncology Hematology Care, University of California, Los Angeles, Froedtert Hospital, Medical College of Wisconsin, Abramson Cancer Center, University of Pennsylvania, Celgene (United States), UC Davis Comprehensive Cancer Center

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2892190472

Cites:

Cited by: 1

Related to: 10